Curative Biotechnology Inc (CUBT)

[Wrangler1]

The NIH has entered into many licensing agreements over the years. What they are doing with CUBT is very common. They will receive a royalty from future product sales. They receive well over $100M a year in royalties from the many licensing agreements they have in place.

Because many, if not most of the technologies developed at the NIH and FDA, are early stage biomedical technologies, the time and development risks to develop a commercial product are high. That is why they collaborate and enter into relationships like the Cooperative Research and Development Agreement they did with CUBT, which owns the worldwide licensing rights of the Metformin eye drop solution, which has huge potential in the multi Billion Dollar AMD treatment market.

It is highly unlikely the National Institute of Health and more specifically the National Eye Institute would have entered into this CRADA with CUBT if they did not see a potential revenue stream through future royalties.